About Us
Science Programs
Pipeline
Clinical Trials
Careers
cONTACT
Resources
Corporate Presentation
Posters, PRESENTATIONS & Publications
MEDIA
Events
News & press releases
Investors
Overview
Stock Information
Analyst Coverage
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Financials & SEC FILINGS
Sec Filings
Quarterly Results
cORPORATE GOVERNANCE
Management Team
Board of Directors
Committee Composition
Governance Documents
News & Press Releases
Get up to speed with Rain!
Filter by year...
2022
2021
2020
2019
2018
Reset Filter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
January
25
,
2022
Rain Therapeutics to Present at Upcoming Virtual Investor Conferences
Download PDf
January
5
,
2022
Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination with Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
Download PDf
December
21
,
2021
Rain Therapeutics to Present at Upcoming Investor Conferences
Download PDf
December
14
,
2021
Rain Therapeutics, Inc. Added to the NASDAQ Biotechnology Index
Download PDf
November
22
,
2021
Rain Therapeutics to Present at Upcoming Investor Conferences
Download PDf
November
19
,
2021
Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
Download PDf
November
10
,
2021
Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
Download PDf
November
9
,
2021
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
Download PDf
November
3
,
2021
Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021
Download PDf
October
25
,
2021
Rain Therapeutics Hosting Research and Development (R&D) Day
Download PDf
Previous
#
Next
